Somerset, NJ - August 3, 2011 - Catalent Pharma Solutions' Clinical Supply Services business, a market leading integrated supplier of clinical trial supplies and services, announces the expansion of its global cold-chain supply capabilities in the US, UK, and Germany pursuant to their commitment to help clients get more products to market faster.
Catalent's expansive cold-chain supply and distribution capabilities allow customers to utilize the company's innovative packaging methods and logistical planning to protect the physical properties of biological products during transport and storage. The expansions will be implemented in all major areas of Catalent's cold-chain storage and distribution, including 2 to 8 degree Celsius and -80 degree Celsius capabilities, in some cases more than tripling existing capacity for storage and distribution.
"Cold-chain storage and distribution capabilities are in increasing demand throughout the industry and our customers are looking to Catalent to provide these services as a trusted partner who can ensure the integrity of their end to end cold-chain needs," said Frank Lis, Vice President and General Manager of Clinical Supply Services. "The steadily increasing number of biological products in development, particularly in prefilled syringes, is fueling the need for refrigerated storage and distribution."
The enhanced global cold-chain expansion, combined with Catalent's offerings in comparator sourcing, clinical packaging and labeling, manufacturing and blinding, distribution and warehousing enables Catalent to better meet the needs of virtually any size clinical trial, with any drug, anywhere in the world - a capability unmatched by competitors in the industry.
"Due to the rapid increase in demand from our customers, these expansions were undertaken with future growth and development needs in mind. Today's investment will allow us to quickly scale-up and meet customer demands should future market growth dictate the need," said Dan Gourley, Director of Global Logistics at Catalent's Philadelphia, PA site.
Catalent expects that cold-chain expansion at Catalent's European sites in Bolton, UK and Schorndorf, Germany will be completed by the end of the year.
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 8,000 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.